

MAINTENANCE AND DISCONTINUATION REFERENCES

1. Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. *Addiction*. 2009;104(2):256-265.
2. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. *J Addict Med*. 2011;5(4):254-263.
3. SAMHSA/CSAT. *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction*. 2004.
4. McNicholas LF. *Buprenorphine: Induction, Dosing and Related Issues*. American Psychiatric Association Sponsored Webinar; 2011.
5. Kosten TR, George TP. *The neurobiology of opioid addiction: implications for treatment*. *NIDA Sci Pract Perspect*. 2002;1(1):13-20.
6. FSMB. *Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office*. *FSMB Website*. 2013.
7. Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Intern Med*. 2014;174(12):1947-1954.
8. Weiss RD, Potter JS, Fiellin DA. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. *Arch Gen Psychiatry*. 2012;68(12):1238-1246.
9. FDA. *FDA approves first buprenorphine implant for treatment of opioid dependence*. *FDA News Events*. May 2016.
10. ASAM. *The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use*. June 2015.
11. Farmer CM, Lindsay D, Williams J, et al. Practice Guidelines for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
12. SAMHSA. *Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update*. Winter 2016.
13. NIDA. *Principles of drug addiction treatment: A research-based guide (Third Edition)*. December 2012.
14. USDHHS. *Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements*. 2016.
15. Emrick CD. *Alcoholics Anonymous and Other 12-Step Groups*. *Textb Subst Abuse Treat*. 1999:403-411.
16. Soyka M. Buprenorphine and buprenorphine/naloxone intoxication in children -- How strong is the risk?. *Curr Drug Abuse Rev*. 2013;6(1):63-70.

17. Martin T, Rocque M. Accidental and Non-Accidental Ingestion of Methadone and Buprenorphine in Childhood: A Single Center Experience, 1999-2009. *Curr Drug Saf.* 2009;6:12-16.
18. Indivior Inc. Suboxone Highlights of Prescribing Information. <http://www.suboxone.com/>. December 2016.
19. Drug Enforcement Administration (DEA). Buprenorphine. 2013.
20. SAMHSA Press Office. Sharp rise in buprenorphine-related emergency department visits from 2005 to 2010. 2013.
21. Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). 2013.
22. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. *US Food Drug Adm Cent Drug Eval Res.* August 2016.
23. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. *US Food Drug Adm Cent Drug Eval Res.* September 2017.
24. Wartenberg A. *Management of Buprenorphine Side Effects.* 2013.
25. Drugs.com. Naloxone. *Drugs.com.* 2015.
26. BMJ. Benzodiazepine overdose. 2017.
27. Substance Abuse and Mental Health Services Administration (SAMHSA). About Buprenorphine Therapy. 2011.
28. SAMHSA. SAMHSA opioid overdose prevention toolkit. 2014.
29. Waknine Y. FDA Approves 7-Day Buprenorphine Pain Patch. 2010.
30. FDA. Medication Guide: Butrans™ CIII (buprenorphine) Transdermal System. 2010.
31. Purdue Pharma. Butrans™ CIII (buprenorphine) Transdermal System. *Butrans Website.* 2010.
32. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. *SupportiveOncology.net.* 2012.
33. Fiellin D. Treatment of acute pain in patients receiving buprenorphine/naloxone. March 2014.
34. Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. *Arch Intern Med.* 2011;171(5):425-431.
35. Alford DP, Compton P, Samet JH. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy. *Ann Intern Med.* 2006;144(2):127-134.
36. Stephenson DK, SAM Committee on Treatment of Opioid Dependence. Draft Guidelines for Physicians Working in California Opioid Treatment Programs. 2008.
37. Weiss Roger D, Potter Jennifer S, Copersino Marc L, et al. Conducting Clinical Research with Prescription Opioid Dependence: Defining the Population. *Am J Addict.* 2010;19(2):141-146. doi:10.1111/j.1521-0391.2009.00017.x.
38. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card. 2015.
39. Melemis SM. Relapse prevention and the five rules of recovery. *Yale J Biol Med.* 2015;88:3.

40. Nielsen S, Hillhouse M, Thomas C. [A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.](#) *J Addict Med.* 2013;7(1):33-38.
41. Dunn KE, Sigmon SC, Strain EC. [The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.](#) *Drug Alcohol Depend.* 2011;119(1-2):1-9.